December 3, 2018 (London time) — Takeda Pharmaceutical Company Limited (TSE:4502) (the “Company or “Takeda”) announces: it has concluded today, December 3, 2018 (London time), a loan agreement with the Japan Bank for International Cooperation (JBIC) for a total capital amount of up to $3,700,000,000 (jBIC loan). The JBIC loan will finance a portion of the funds, commitments related to the acquisition of Shire plc (“Shire”) and commitments made under the 364-day bridge credit contract entered into in connection with the acquisition on May 8, 2018 (as amended on June 8, 2018 and October 26, 2018) (the “bridge credit contract”). We are pleased to have received this loan from JBIC, an organization that promotes the maintenance and strengthening of the international competitiveness of Japanese industry,” said Costa Saroukos, Takeda`s CFO. “The refinancing program for our bridge investment is thus completed at an overall interest rate for the various components of the refinancing, which we believe supports our intention to maintain our well-established dividend policy and investment degree rating. We believe that JBIC`s participation in the financing of the acquisition will further strengthen our commitment to accelerate our transformation into a global biopharmaceutical leader based in Japan.In, in accordance with Rule 26 of the City Code on Takeovers and Mergers, and that a copy of the JBIC loan will be published on Takeda`s website and will be available no later than 12:00 p.m. (London time) on the day of this announcement at www.takeda.com/investors/offer-for-shire. Please note that the acquisition remains subject to certain conditions, including the agreement of the shareholders of both companies. Osaka, Japan, August 3, 2020 — Takeda Pharmaceutical Company Limited (headquartered: Chuo-ku, Osaka; (TSE:4502/NYSE:TAK), “Takeda”) today decided to proceed with an absorption merger (the “merger”) of Shire Japan KK, Takeda`s wholly-paid subsidiary. Following the acquisition of Shire plc (“Shire” last year), Takeda`s transformation into a global company with the top 10 biopharmaceuticals accelerated. Takeda is now an integrated, values-based company focused on converting science into life-changing drugs. In order to continue to grow and efficiency, the subsidiary of Shire Japan KK is now admitted to Takeda. Japanische MediaKazumi Kobayashikazumi.email@example.com+81 (0) 3-3278-2095Medien außerhalb JapanStsuyoshi Tadatsuyoshi.firstname.lastname@example.org+1 (617) 551-2933 Ankündigung einer Fusion (einfache Fusion/Kurzformfusion) mit einer hundertprozentigen Tochtergesellschaft Media and Investor Contacts:Takeda (Investor Relations)Takashi Okubotakeda.email@example.com+81 3 3278 2306Takeda (Medien – innerhalb Japans)Kazumi Kobayashikazumi.firstname.lastname@example.org+8 1 3 3278 2095Takeda (Medien – außerhalb Japans)Elissa JohnsenElissa.Johnsen@takeda.com+1 312 285 3203Tsuyoshi TadaTsuyoshi.Tada@takeda.com+1 617 551 2933About Takeda Pharmaceutical CompanyTakeda Pharmaceutical Company Limited (TSE: 4502) ist ein globales, forschungs- und entwicklungsorientiertes Pharmaunternehmen, das sich der Verbesserung der Gesundheit und einer besseren Zukunft für Patienten verschrieben hat, indem es Wissenschaft in lebensverändernde Arzneimittel übersetzt.